Hypoxia - A key regulatory factor in tumour growth

Nature Reviews Cancer

Volumn 2, Issue 1, 2002, Pages 38-47

  Harris, Adrian L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CALPHOSTIN C; DIPHENYLIODONIUM SALT; ERYTHROPOIETIN; GEFITINIB; HERBIMYCIN; HYPOXIA INDUCIBLE FACTOR 1; MANNOHEPTULOSE; RAPAMYCIN; THROMBOSPONDIN; TRASTUZUMAB; WORTMANNIN; ARNT PROTEIN, HUMAN; ARNT PROTEIN, MOUSE; AROMATIC HYDROCARBON RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA BINDING PROTEIN; ENDOTHELIAL CELL GROWTH FACTOR; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR 2, ALPHA SUBUNIT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOKINE; NUCLEAR PROTEIN; ONCOPROTEIN; OXYGEN; PRODRUG; PROTEIN TYROSINE KINASE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; EMBRYO DEVELOPMENT; GENETIC STABILITY; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; CELL DIVISION; CELL HYPOXIA; DIMERIZATION; DNA DAMAGE; DRUG SCREENING; FORECASTING; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; METABOLISM; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PH; PHYSIOLOGY; PRENATAL DEVELOPMENT; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIVISION; CELL HYPOXIA; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIMERIZATION; DNA DAMAGE; DNA-BINDING PROTEINS; EMBRYONIC AND FETAL DEVELOPMENT; ENDOTHELIAL GROWTH FACTORS; ERYTHROPOIETIN; FORECASTING; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; NUCLEAR PROTEINS; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYGEN; PRODRUGS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036359548     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc704     Document Type: Review

References (117)

1. Thomlinson, R. & Gray, L. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Canc. 9, 539-549 (1955).
2. Brown, J. M. & Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416 (1998).
3. Prabhakar N. R. Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J. Appl. Physiol. 90, 1986-1994 (2001).
4. Wouters, B. G. & Brown, J. M. Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy. Radiat. Res 147, 541-550 (1997).
5. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266-276 (2001).
6. Hockel, M., Schlenger, K., Hockel, S. & Vaupel, P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59, 4525-4528 (1999).
7. Dang, C. V. & Semenza, G. L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24, 68-72 (1999).
8. 2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995).
9. Carrero, P. et al. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor-1α. Mol. Cell Biol. 20, 402-415 (2000).
10. Lando, D., Pongratz, I., Poellingers, L. & Whitelaw, M. L. A redox mechanism controls differential DNA binding activities of hypoxia-inducible factor (HIF)-1α and the HIF-like factor. J. Biol. Chem. 275, 4618-4627 (2000).
11. Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein J. Biol. Chem. 275, 25733-25741 (2000).
12. Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423-427 (2000).
13. Kamura, T. et al. Activation of HIF-1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430-10435 (2000).
14. Tanimoto, K., Makino, Y., Pereira, T. & Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19, 4298-4309 (2000). References 11-14 report that VHL protein modifies HIF-1α by ubiquitylation.
15. Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 (1999). The first to show that mutations in VHL caused upregulation of HIF-1α, coupling a tumour-suppressor pathway to HIF-1 signalling.
16. Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. Structure of the VHL-elongin-C-elongin-B complex: implications for VHL tumor suppressor function. Science 284, 455-461 (1999).
17. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
18. 2 sensing. Science 292, 464-468 (2001). References 17 and 18 were the first descriptions of an enzyme that covalently modifies HIF-1α in an oxygen-dependent manner.
19. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20, 5197-5206 (2001).
20. 2 sensing. J. Biol. Chem. 275, 25130-25138 (2000).
21. Srinivas, V. et al. Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. J. Biol. Chem. 276, 21995-21998 (2001).
22. Vaux, E. C., Metzen, E., Yeates, K. M. & Ratcliffe, P. J. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98, 296-302 (2001).
23. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
24. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001). References 23 and 24 describe the characterization of three enzymes that act as oxygen sensors, using HIF-1α as a substrate and requiring oxygen.
25. Ryan, H. E., Lo, J. & Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17, 3005-3015 (1998). This study, along with references 28 and 44, shows that HIF-1α has a significant role in tumour growth in vivo.
26. Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W. & McKnight, S. L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12, 3320-3324 (1998).
27. Peng, J., Zhang, L., Drysdale, L. & Fong, G. H. The transcription factor EPAS-1/hypoxia-inducible factor-2α plays an important role in vascular remodeling. Proc. Natl Acad. Sci. USA 97, 8386-8391 (2000).
28. Maxwell, P. H. et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 94, 8104-8109 (1997).
29. Talks, K. L. et al. Expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421 (2000). The authors used a monoclonal antibody against HIF-1α to examine its expression and distribution in a variety of solid tumours. They observed nuclear localization of HIF-1α and -2α in subsets of the tumour cells, and reported that HIF-2α was also strongly expressed by subsets of tumour-associated macrophages.
30. Zhong, H. et al. Overexpression of hypoxia-inducible factor-1α in common human cancers and their metastases Cancer Res. 59, 5830-5835 (1999). HIF-1α expression was analysed by immunohistochemistry in 179 tumour specimens, and found to be overexpressed in a variety of tumour types. HIF-1α expression was also correlated with aberrant p53 accumulation and cell proliferation. These results provided the first clinical data indicating that HIF-1α was important for human cancer progression.
31. Elson, D. A., Ryan, H. E., Snow, J. W., Johnson, R. & Arbeit, J. M. Coordinate up-regulation of hypoxia inducible factor (HIF)-1α and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res. 60, 6189-6195 (2000).
32. Krieg, M. et al. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443 (2000).
33. Hanahan, D. & Weinberg, R. A The hallmarks of cancer. Cell 100, 57-70 (2000).
34. Denko, N. et al. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin. Cancer Res. 6, 480-487 (2000).
35. Koong, A. C. et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60, 883-887 (2000).
36. Wykoff, C. C., Pugh, C. W., Maxwell, P. H., Harris, A. L. & Ratcliffe, P. J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19, 6297-6305 (2000).
37. Lal, A. et al. Transcriptional response to hypoxia in human tumors. J. Natl Cancer Inst. 93, 1337-1343 (2001). References 35-37 described a large number of hypoxia-regulated genes, among which there are many proangiogenic pathways.
38. Berra, E. et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60, 1171-1178 (2000).
39. Conrad, P. W., Beitner-Johnson, D. & Millhorn, D. E. EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J. Biol. Chem. 274, 33709-33713 (1999).
40. Chen, E. Y., Mazure, N. M., Cooper, J. A. & Giaccia, A. J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 61, 2429-2433 (2001).
41. Zundel, W. et al. Loss of PTEN facilitates HIF-1-mediated gene expression Genes Dev. 14, 391-396 (2000). One of several papers showing that the PI3K pathway regulates HIF through a hypoxia-independent pathway.
42. Ryan, H. E. et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60, 4010-4015 (2000).
43. Mazurek, S., Boschek, C. B. & Eigenbrodt, E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J. Bioenerg. Biomembr. 29, 315-330 (1997).
44. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
45. Yu, J. L. et al. Heterogeneous vascular dependence of tumor cell populations. Am. J. Pathol. 158, 1325-1334 (2001).
46. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G. & Livingston, D. M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Med. 6, 1335-1340 (2000). Revealed that blockade of HIF-1 signalling by a peptide can completely inhibit tumour growth in vivo.
47. de Fraipont, F., Nicholson, A. C., Feige, J. J. & Van Meir, E. G. Thrombospondins and tumor angiogenesis. Trends Mol. Med. 7, 401-407 (2001).
48. Seagroves, T. N. et al. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells Mol. Cell Biol. 21, 3436-3444 (2001).
49. Chen, C. H., Pore, N., Behrooz, A., Ismail, B.-F. & Maity, A. Regulation of GLUT1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia. J. Biol. Chem. 276, 9519-9525 (2001).
50. Seimiya, H. et al. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochem. Biophys. Res. Commun. 260, 365-370 (1999)
51. Coquelle, A., Toledo, F., Stern, S., Bieth, A. & Debatisse, M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 2, 259-265 (1998).
52. Yuan, J., Narayanan, L., Rockwell, S. & Glazer, P. M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 60, 4372-4376 (2000).
53. Kim, M. S. et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Med. 7, 437-443 (2001).
54. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl Acad. Sci. USA 97, 9082-9087 (2000).
55. Vande Verde, C. et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol. Cell Biol. 20, 5454-5468 (2000).
56. Sowter, H. M., Ratcliffe, P. J., Watson, P., Greenberg, A. H. & Harris, A. L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61, 6669-6673 (2001).
57. Suzuki, H., Tomida, A. & Tsuruo, T. Dephosphorylated hypoxia-inducible factor-1α as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20, 5779-5788 (2001).
58. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379, 88-91 (1996). Shows that hypoxia selects for a more aggressive tumour phenotype in vivo.
59. Koumenis, C. et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 21, 1297-1310 (2001).
60. Soengas, M. S. et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156-159 (1999). Defines the key pathways of hypoxia-induced apoptosis.
61. An, W. G. et al. Stabilization of wild-type p53 by hypoxia-inducible factor-1α. Nature 392, 405-408 (1998).
62. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor-1α. Genes Dev. 14, 34-44 (2000).
63. Dong, Z. et al. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia, HIF-1-independent mechanisms J. Biol. Chem. 276, 18702-18709 (2001). Reports non-HIF-1 pathways that are important for cell survival that is regulated by hypoxia.
64. Ivanov, S. V. et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl Acad. Sci. USA 95, 12596-2601 (1998).
65. Wykoff, C. C. et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res. 60, 7075-7083 (2000). Shows that acid pH in tumours might be determined by novel hypoxia-regulated pathways.
66. Loncaster, J. A. et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61, 6394-6399 (2001).
67. Chia, S. K. et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19, 3660-3668 (2001)
68. Yamagata, M., Hasuda, K., Stamato, T. & Tannock, I. F. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 77, 1726-1731 (1998).
69. Gardner, L. B. et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276, 7919-7926 (2001)
70. Green, S. L., Freiberg, R. A. & Giaccia, A. J. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell Biol. 21, 1196-1206 (2001).
71. Raleigh, J. A. et al. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin. Cancer Res. 6, 855-862 (2000).
72. Taylor, C. T., Furuta, G. T., Synnestvedt, K. & Colgan, S. P. Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc. Natl Acad. Sci. USA 97, 12091-12096 (2000).
73. Schmedtje, J. F. Jr, Ji, Y. S., Liu, W. L., DuBois, R. N. & Runge, M. S. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 272, 601-608 (1997).
74. Yan, S. F. et al. Hypoxia-associated induction of early growth response-1 gene expression. J. Biol. Chem. 274, 15030-15040 (1999).
75. Yan, S. F., Pinsky, D. J. & Stern, D. M. A pathway leading to hypoxia-induced vascular fibrin deposition. Semin Thromb. Hemost. 26, 479-483 (2000).
76. Murphy, B. J. et al. Activatin of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer Res 59, 1315-1322 (1999).
77. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575-583 (2001).
78. Littlewood, T. J. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol. 28, 49-53 (2001).
79. Littlewood, T. J., Bajetta, E., Nortier J. W., Vercammen. E. & Rapoport, B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19, 2865-2874 (2001).
80. Bernier, J. et al. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). Radiother. Oncol. 55, 111-119 (2000).
81. Cohen, J.-E. et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. 61, 2289-2293 (2001).
82. Wardman, P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr. Med. Chem. 8, 739-761 (2001).
83. von Pawel, J. et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 18, 1351-1359 (2000).
84. Lewis, J. S. & Welch, M. J. PET imaging of hypoxia. J. Nucl. Med. Allied Sci. 45, 183-188 (2001).
85. Sun, X. et al. Gene transfer of antisense hypoxia inducible factor-1 a enhances the therapeutic efficacy of cancer immunotherapy. Gene Ther 8, 638-645 (2001). Describes how the synergy between anti-HIF-1 therapy and immunotherapy might be an important model for future clinical trials.
86. Bhattacharya, S. et al. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13, 64-75 (1999).
87. Gleadle, J. M., Ebert, B. L. & Ratcliffe, P. J. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia Implications for the mechanism of oxygen sensing. Eur. J. Biochem. 234, 92-99 (1995).
88. Dachs, G. U. et al. Targeting gene expression to hypoxic tumor cells. Nature Med. 3, 515-520 (1997). Shows that the HIF-1 pathway can be manipulated to activate therapeutic genes at specific oxygen tensions in vivo.
89. Lemmon, M. J. et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 4, 791-796 (1997).
90. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W. & Vogelstein, B. Combination bacteriolytic therapy for the treatment of experimental tumours. Proc. Natl Acad. Sci. USA 2001 Nov 27; [epub ahead of print].
91. Griffiths, L. et al. The macrophage: a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7, 255-262 (2000).
92. Koshikawa, N., Takenaga, K., Tagawa, M. & Sakiyama, S. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer. Res. 60, 2936-2941 (2000).
93. Pioli, P. A. & Rigby W. F. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression J. Biol. Chem. 274, 40346-40352 (2001). Discusses the role of RNA stabilization in hypoxia gene regulation, particularly the direct role of VHL.
94. Ohh, M. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 7, 959-968 (1998).
95. Okuda, H. et al. Direct interaction of the β-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem. Biophys. Res. Commun. 263, 491-497 (1999).
96. Kamura, T., Conrad, M. N., Yan, Q., Conaway, R. C. & Conaway J. W. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2 Genes Dev. 13, 2928-2933 (1999).
97. Yamashita, K., Discher D. J., Hu, J., Bishopric, N. H. & Webster, K. A. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J. Biol. Chem. 276, 12645-12653 (2001).
98. Maltepe, E., Keith, B., Arsham, A. M., Brorson, J. R. & Simon, M. C. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia Biochem. Biophys. Res. Commun. 273, 231-238 (2000).
99. Hogenesch, J. B., Gu, Y. Z., Jain, S. & Bradfield, C. A. The basic helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc. Natl Acad. Sci. USA 95, 5474-5479 (1998).
100. Thrash-Bingham, C. A. & Tartof, K. D. αHIF: a natural antisense transcript overexpressed in human renal cancer and dunng hypoxia. J. Natl Cancer Inst. 91, 143-151 (1999).
101. Levy, N. S., Chung, S., Furneaux, H. & Levy, A. P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273, 6417-6423 (1998).
102. Levy, N. S., Goldberg, M. A. & Levy, A. P. Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim. Biophys. Acta 1352, 167-173 (1997).
103. Palmer, L. A., Semenza, G. L., Stoler, M. H. & Johns, R. A. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am. J. Physiol. 274, L212-L219 (1998).
104. Zelzer, E. et al. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT EMBO J. 17, 5085-5094 (1998).
105. Richard, D. E., Berra, E. & Pouyssegur, J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor-1α in vascular smooth muscle cells. J. Biol. Chem. 275, 26765-26771 (2000).
106. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C. & Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor-1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004 (2001).
107. Sodhi, A. et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor-1α. Cancer Res. 60, 4873-4880 (2000).
108. Hirota, K. & Semenza, G. L. Rac1 activity is required for the activation of hypoxia-inducible factor-1. J. Biol. Chem. 276, 21166-21172 (2001).
109. Jiang, B. H., Agani, F., Passaniti, A. & Semenza, G. L. v-SRC induces expression of hypoxia-inducible factor-1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57, 5328-5335 (1997).
110. Aragones, J. et al. Evidence for the involvement of diacylglycerol kinase in the activation of hypoxia-inducible transcription factor-1 by low oxygen tension. J. Biol. Chem. 276, 10548-10555 (2001).
111. Lee, S. W. et al. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem. Biophys. Res. Commun, 268, 456-461 (2000).
112. Wang, G. L., Jiang, B. H. & Semenza, G. L. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun. 216, 669-675 (1995).
113. Blancher, C., Moore, J. W., Talks, K. L., Houlbrook, S. & Harris, A. L. Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60, 7106-7113 (2000).
114. Hur, E., Chang, K. Y., Lee, E., Lee, S. K. & Park, H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the transactivation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1α. Mol. Pharmacol. 59, 1216-1224 (2001).
115. Zhong, H. et al. Modulation of hypoxia-inducible factor-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000). Reports that oncogenic signalling pathways regulate HIF-1α, independently of hypoxia. Inhibitors of these pathways also block hypoxia-induced HIF-1 signalling.
116. Board, M., Colquhoun, A. & Newsholme, E. A. High Km glucose-phosphorylating (glucokinase) activities in a range of tumour cell lines and inhibition of rates of tumour growth by the specific enzyme inhibitor mannoheptulose. Cancer Res. 55, 3278-3285 (1995).
117. Schmaltz, C., Hardenbergh, P. H., Wells, A. & Fisher, D. E. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol. 18, 2845-2854 (1998). Shows that cell death in hypoxia might be mediated by low pH rather than low oxygen.